We want the hardest questions asked.
Heritable gene editing is one of the most consequential and most debated technologies of our time. Origin does not shy away from that debate. We believe the responsible path is to work transparently, under oversight, and to let the data decide.
How We Work
Three pillars
The goal is not to move fast and hope. It is to build the evidence and the norms that let this be done, and be trusted.
Oversight first.
Origin is the first company to obtain IRB (ethics board) approval for human embryo gene editing. Independent review is built into how we work, not added after.
Evidence before advocacy.
As our CEO puts it, the aim is to prove to the public, the scientific community, the regulators, and the bioethicists that this technology can be safe, if the data shows that it is, and only then should it be considered for clinical use.
A legal, consent-based framework.
Origin's policy work supports clear right-to-try pathways so that any future clinical step happens with informed consent and legal clarity, not in a gray zone.
When a safe and effective intervention can prevent a severe inherited disease, choosing not to develop or offer it is not a morally neutral position. The obligation of medicine is not only to avoid harm, but to prevent avoidable suffering when effective interventions exist.
Questions We Get Asked
Frequently Asked Questions
Heritable gene editing is one of the most consequential and most debated technologies of our time. Origin does not shy away from that debate: the responsible path is to work transparently, under independent oversight, and to let the data decide.
Origin is the first company to obtain IRB (ethics board) approval for human embryo gene editing. Independent review is built into how the company works, not added after the fact.
No. The aim is to prove to the public, the scientific community, the regulators, and the bioethicists that this technology can be safe, if the data shows that it is. Only then should it be considered for clinical use.
Origin's policy work supports clear right-to-try pathways so that any future clinical step happens with informed consent and legal clarity, rather than in a regulatory gray zone.
That view made sense when genome editing was limited by unpredictable repair, mosaicism, and chromosomal abnormalities. As precision improves, the ethical question changes with it. When a safe and effective intervention can prevent severe inherited disease, choosing not to develop it is not a morally neutral position, and if rigorous evaluation shows it to be safe and effective, continued prohibition would itself require justification.